Pivotal phase I pharmacokinetic study of bevacizumab biosimilar (ONS-1045) compared with Avastin in volunteers

Trial Profile

Pivotal phase I pharmacokinetic study of bevacizumab biosimilar (ONS-1045) compared with Avastin in volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Lung cancer
  • Focus Pharmacokinetics; Registrational
  • Sponsors Oncobiologics
  • Most Recent Events

    • 05 Oct 2015 Primary endpoint (Area under the time-concentration curve from first time point extrapolated to infinity) has been met, according to Oncobiologics media release.
    • 20 Apr 2015 New trial record
    • 15 Apr 2015 Dosing in this pivotal study has been completed, according to an Oncobiologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top